Arcus Biosciences Shares Soar 5.15% on Thursday, June 08 as Buyers Push Price Upward
June 15, 2023
☀️Trending News
Arcus Biosciences ($NYSE:RCUS) Inc. is a publicly traded biopharmaceutical company based in Hayward, California. They focus on developing novel therapies that target tumor immunology, DNA damage response and epigenetics. On Thursday, June 08, their stock experienced an upsurge of 5.15%, as buyers pushed the stock price higher in response to positive news about their drug programs and clinical trials.
This increase in stock value comes as a strong endorsement of the company’s commitment to developing treatments for some of the most challenging diseases in oncology, and has put Arcus Biosciences Inc. firmly on the path towards increased share price. Investors have taken note of the encouraging developments at Arcus Biosciences and are likely to continue to show confidence in their potential for future growth.
Analysis
At GoodWhale, we have conducted an in-depth analysis of ARCUS BIOSCIENCES‘s fundamentals and have assigned it a Risk Rating of Medium. This indicates that the company has an acceptable level of risk in terms of its financial and business aspects. We have detected three risk warnings in the balance sheet, cashflow statement and financial journal of ARCUS BIOSCIENCES. For more details, please register with us to gain access to this information. We can help you make an informed decision about whether ARCUS BIOSCIENCES is a good investment for you. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arcus Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 119 | -279 | -234.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arcus Biosciences. More…
| Operations | Investing | Financing |
| -314 | -16 | 19 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arcus Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.25k | 654 | 8.21 |
Key Ratios Snapshot
Some of the financial key ratios for Arcus Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 99.4% | – | -230.3% |
| FCF Margin | ROE | ROA |
| -273.9% | -27.2% | -13.7% |
Peers
The company’s product candidates include AB928, AB154 and AB122, which are in various clinical trials for the treatment of solid tumors and hematologic malignancies. Arcus Biosciences Inc’s competitors include Immunic Inc, G1 Therapeutics Inc, Ocuphire Pharma Inc.
– Immunic Inc ($NASDAQ:IMUX)
The company’s market cap is $56.93M as of 2022 and its ROE is -44.31%. The company is engaged in the development of immunotherapies for the treatment of cancer.
– G1 Therapeutics Inc ($NASDAQ:GTHX)
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
G1 Therapeutics has a market cap of $366.9 million and a return on equity of -159.15%. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
– Ocuphire Pharma Inc ($NASDAQ:OCUP)
Ocuphire Pharma Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing therapies to treat ocular disorders. Its lead product candidate is Nyxol, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. The company was founded by Derek J. Rappaport and Nancy S. Lurie on March 1, 2006 and is headquartered in Boca Raton, FL.
Summary
Arcus Biosciences Inc.’s stock price has been on an upward trajectory in the last few days, with a 5.15% increase on Thursday, June 08. This was driven by buyers who are optimistic about the performance of the company. Despite this short-term upside momentum, investors should be aware that stock prices can be volatile, and so it is important to carry out thorough research before investing in the company. Some key questions to ask when considering investing in Arcus Biosciences Inc. include: Is the company profitable?
Are they financially stable? Are there any risks or potential red flags? Analysing the company’s financials, competitive environment and management team can help investors make an informed decision.
